XORTX Therapeutics Inc（XRTX）股票分析

AI 分析 of XORTX Therapeutics Inc (XRTX)

賣出

XORTX Therapeutics Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The stock is currently priced at $0.87, which is close to its 52-week low of $0.83, indicating weak market performance. Additionally, the RSI is at a low 24.41, suggesting the stock is oversold, but this does not guarantee a rebound. The company has reported a staggering year-to-date change of -69.47% and has a forward P/E ratio of 0.9621, indicating potential undervaluation but also reflecting ongoing financial struggles. The main risk is its negative net income, which reached -1,690,734 USD in Q2 2026, highlighting ongoing financial instability.

估值指標

XORTX Therapeutics Inc（XRTX）目前預期本益比為 0.96，5 年平均預期本益比為 -0.97。

預期本益比

高估

5 年均值 P/E

-0.97

目前P/E

0.96

高估

0.17

低估

-2.12

預期 EV/EBITDA

合理

5 年均值 EV/EBITDA

0.08

目前EV/EBITDA

0.00

高估

0.33

低估

-0.17

預期股價營收比

合理

5 年均值 P/S

0.37

目前P/S

0.08

高估

1.34

低估

-0.61

Alphio AI 對 XRTX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%XRTX

$0.91

情境價格

基

基準

基準 · 50%XRTX

$0.82

情境價格

悲

悲觀

悲觀 · 25%XRTX

$0.78

情境價格

XRTX 常見問題 —— 由 Alphio AI 解答

XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

XORTX Therapeutics Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The stock is currently priced at $0.87, which is close to its 52-week low of $0.83, indicating weak market performance. Additionally, the RSI is at a low 24.41, suggesting the stock is oversold, but this does not guarantee a rebound. The company has reported a staggering year-to-date change of -69.47% and has a forward P/E ratio of 0.9621, indicating potential undervaluation but also reflecting ongoing financial struggles. The main risk is its negative net income, which reached -1,690,734 USD in Q2 2026, highlighting ongoing financial instability.